Differences in market access and reimbursement processes are an important factor in determining the ...
Read moreThis resolution includes proposed reforms to the market access (including pricing) landscape designe...
Read more"Market Access" describes activities and processes that pharmaceutical and biotech companies underta...
Read morePrescription drug prices in the US rank among the highest in the world and the US spent $1220 on ph...
Read moreThe Westminster Health Forum organise senior level conferences on public policy relating to health a...
Read moreWith the UKs withdrawal from the European Union, NICE’s relationship with EMA and indeed, the para...
Read moreMaximising the cost-saving potential of biosimilars remains a topic of much interest to payers and p...
Read moreDiscussing the benefits of seeking early scientific advice and what companies need to take into cons...
Read moreWhat are the pro’s and cons of seeking NICE approval using the Medical Technologies Evaluation Pro...
Read morePharmaceutical companies are incorporating payer / HTA needs into their clinical and commercial laun...
Read more